[HTML][HTML] Trial of deferiprone in Parkinson's disease
Background Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol, JC Corvol… - THE NEW ENGLAND …, 2022 - iris.unisa.it
BACKGROUNDIron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche… - New England …, 2022 - researchinformation.amsterdamumc …
Background Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol, JC Corvol… - New England Journal …, 2022 - diva-portal.org
BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
Trial of Deferiprone in Parkinson's Disease.
D Devos, J Labreuche, O Rascol, JC Corvol… - The New England …, 2022 - europepmc.org
Background Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol… - New England Journal …, 2022 - eprints.ncl.ac.uk
Abstract© 2022 Massachusetts Medical Society. Background Iron content is increased in the
substantia nigra of persons with Parkinson's disease and may contribute to the …
substantia nigra of persons with Parkinson's disease and may contribute to the …
[PDF][PDF] Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol, JC Corvol… - 2022 - repository.ubn.ru.nl
BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
[引用][C] Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol, JC Corvol… - 2022 - oparu.uni-ulm.de
Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol, JC Corvol… - New England Journal …, 2022 - hal.science
Background Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
Trial of Deferiprone in Parkinson's Disease
D Devos, J Labreuche, O Rascol… - The New England …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Iron content is increased in the substantia nigra of persons with Parkinson's
disease and may contribute to the pathophysiology of the disorder. Early research suggests …
disease and may contribute to the pathophysiology of the disorder. Early research suggests …